MAIA Biotechnology, Inc.
Veridion Score
Composite trend over time
Why is MAIA moving today?
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for MAIA.
MAIA insider activity
MAIA Biotechnology, Inc.
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for MAIA.
MAIA contract awards, year to date.
Public federal awards linked to this ticker.
MAIA lobbying filings, year to date.
Registered lobbying filings matched to MAIA Biotechnology, Inc..